FDA approves oral Wegovy for weight loss and cardiovascular risk reduction

statnews.com

The FDA approved an oral version of Novo Nordisk's Wegovy, marking the first GLP-1 pill for obesity. The pill, also approved to reduce cardiovascular risks, showed similar weight loss efficacy to its injectable form in studies and is set to launch in January. This approval could increase access to GLP-1 treatments, though pricing and competition from other oral options like Eli Lilly's orforglipron will be key factors.


With a significance score of 5.5, this news ranks in the top 0.7% of today's 30790 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: